FR12C0052I2 - Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel - Google Patents

Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel

Info

Publication number
FR12C0052I2
FR12C0052I2 FR12C0052C FR12C0052C FR12C0052I2 FR 12C0052 I2 FR12C0052 I2 FR 12C0052I2 FR 12C0052 C FR12C0052 C FR 12C0052C FR 12C0052 C FR12C0052 C FR 12C0052C FR 12C0052 I2 FR12C0052 I2 FR 12C0052I2
Authority
FR
France
Prior art keywords
serotonin reuptake
reuptake inhibitor
selective serotonin
sexual dysfunction
treate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR12C0052C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APBI Holdings LLC
Original Assignee
APBI Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22542905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0052(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR12C0052I1 publication Critical patent/FR12C0052I1/fr
Application filed by APBI Holdings LLC filed Critical APBI Holdings LLC
Application granted granted Critical
Publication of FR12C0052I2 publication Critical patent/FR12C0052I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR12C0052C 1999-09-03 2012-08-29 Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel Active FR12C0052I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15243599P 1999-09-03 1999-09-03
PCT/US2000/020788 WO2001017521A1 (en) 1999-09-03 2000-08-22 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Publications (2)

Publication Number Publication Date
FR12C0052I1 FR12C0052I1 (de) 2012-05-10
FR12C0052I2 true FR12C0052I2 (fr) 2013-08-16

Family

ID=22542905

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0052C Active FR12C0052I2 (fr) 1999-09-03 2012-08-29 Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel

Country Status (34)

Country Link
US (4) US7718705B1 (de)
EP (3) EP1889614A3 (de)
JP (1) JP3194734B2 (de)
KR (1) KR100719977B1 (de)
CN (1) CN1222283C (de)
AT (1) ATE318135T1 (de)
AU (1) AU762934B2 (de)
BE (1) BE2012C040I2 (de)
BG (1) BG65677B1 (de)
BR (1) BR0014166A (de)
CA (1) CA2383785C (de)
CY (1) CY2012028I2 (de)
CZ (1) CZ299712B6 (de)
DE (2) DE122009000036I2 (de)
DK (1) DK1225881T3 (de)
EA (1) EA004101B1 (de)
EE (1) EE05315B1 (de)
ES (2) ES2256032T3 (de)
FR (1) FR12C0052I2 (de)
HK (2) HK1047545B (de)
HR (1) HRP20020189A2 (de)
HU (1) HU229150B1 (de)
IL (2) IL148159A0 (de)
LU (1) LU92204I2 (de)
MX (1) MXPA02001811A (de)
MY (1) MY125490A (de)
NO (2) NO330562B1 (de)
NZ (1) NZ517038A (de)
PL (1) PL211402B1 (de)
SI (1) SI1225881T1 (de)
TW (3) TWI312678B (de)
UA (1) UA75580C2 (de)
WO (1) WO2001017521A1 (de)
ZA (1) ZA200201407B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
EP1889614A3 (de) * 1999-09-03 2010-09-22 APBI Holdings, LLC Verfahren zur Verwendung selektiver Serotonin-Wiederaufnahmehemmer mit schnellem Wirkungseintritt zur Behandlung sexueller Dysfunktionen
CN1289071C (zh) 2001-03-16 2006-12-13 Dmi生物科学公司 曲马朵物质在制备用于延缓男性射精的药物中的用途
MXPA03008807A (es) 2001-03-29 2004-02-12 Bristol Myers Squibb Co Derivados de ciclopropilindol como inhibidores selectivos de recaptacion de serotonina.
CA2410966C (en) * 2002-11-01 2005-11-22 Craig J. Hudson Sexual desire and performance enhancement with protein-bound tryptophan
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
DE102009015702A1 (de) 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
DE102009058321A1 (de) 2009-12-15 2011-06-16 Ratiopharm Gmbh Schmelztablette, enthaltend Dapoxetin
MX2013000001A (es) 2010-07-06 2013-05-01 Navipharm Co Ltd Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.
RU2463033C2 (ru) * 2010-08-06 2012-10-10 Василий Федорович Пятин Способ лечения преждевременной эякуляции
CN103100085A (zh) * 2011-11-09 2013-05-15 上海兰蒂斯生物医药科技有限公司 一种药物组合物
CN103130660B (zh) * 2011-11-25 2014-09-17 厦门福满药业有限公司 一类达泊西汀的酸式盐及其晶体,以及晶体的制备方法
WO2014042416A1 (ko) * 2012-09-13 2014-03-20 주식회사 씨티씨바이오 다폭세틴 유리염기를 함유하는 경구용 조성물
KR101432905B1 (ko) 2012-12-11 2014-08-21 가톨릭대학교 산학협력단 다폭세틴을 유효성분으로 포함하는 유전적 통증 치료용 약학 조성물
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
CN103735525B (zh) * 2014-02-12 2015-05-06 江苏仁寿药业有限公司 一种达泊西汀片剂及制备方法
CN106659755A (zh) * 2014-08-12 2017-05-10 王天欣 一种处理哺乳动物性功能障碍的方法、药品及药品配方
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) * 2016-11-30 2018-06-07 Wang tian xin Therapeutical methods, formulations and nutraceutical formulations
TR201620151A2 (en) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN
CN113143879A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀缓释片的制备方法
CN113181127A (zh) * 2021-05-07 2021-07-30 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀微丸片的制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4329356A (en) * 1980-10-31 1982-05-11 Eli Lilly And Company Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5082667A (en) 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5589511A (en) 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5151448A (en) * 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5151488A (en) * 1991-11-12 1992-09-29 The Mead Corporation Liquid crystal polymers containing a repeating bisoxazole structure
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5292962A (en) 1992-12-11 1994-03-08 Eli Lilly And Company Intermediates to 1-phenyl-3-naphthalenyloxy-propanamines
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ZA93694B (en) 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
IT1264965B1 (it) 1993-11-12 1996-10-17 Giorgio Cavallini Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
KR100374924B1 (ko) 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
IL123583A (en) 1995-10-13 2003-07-31 Neurosearch As 3-substituted -8-azabicyclo [3,2,1] oct-2-ene derivatives, their preparation and pharmaceutical compositions containing them
US5758911A (en) * 1996-02-07 1998-06-02 Northrop Grumman Corporation Linear motion wind driven power plant
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5830500A (en) 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CN1475209A (zh) 1997-07-01 2004-02-18 �Ʒ� 舍曲林的缓释剂型
IL152330A0 (en) 1997-07-01 2003-05-29 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
KR100371730B1 (ko) 1997-07-01 2003-02-07 화이자 프로덕츠 인코포레이티드 세르트랄린의 젤라틴 캡슐화된 용액 투여형
FR2765483B1 (fr) * 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
CA2335336A1 (en) 1998-06-19 1999-12-23 James Edmund Audia Inhibition of serotonin reuptake
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6150376A (en) 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
PL348119A1 (en) 1998-10-13 2002-05-06 Pfizer Prod Inc Sertraline oral concentrate
EP1180021A4 (de) 1999-05-06 2005-01-19 Pentech Pharmaceuticals Inc Behandlung der prämaturen ejakulation und dazugehöriger kit
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
EP1889614A3 (de) * 1999-09-03 2010-09-22 APBI Holdings, LLC Verfahren zur Verwendung selektiver Serotonin-Wiederaufnahmehemmer mit schnellem Wirkungseintritt zur Behandlung sexueller Dysfunktionen

Also Published As

Publication number Publication date
BG106461A (en) 2002-12-29
MY125490A (en) 2006-08-30
EP1889614A2 (de) 2008-02-20
BR0014166A (pt) 2002-05-14
DK1225881T3 (da) 2006-06-12
ATE318135T1 (de) 2006-03-15
HU229150B1 (hu) 2013-09-30
EP1889614A3 (de) 2010-09-22
MXPA02001811A (es) 2002-08-06
TW201018459A (en) 2010-05-16
US20050215617A1 (en) 2005-09-29
HUP0202687A3 (en) 2006-03-28
NO2012015I1 (no) 2012-09-11
NO20021035L (no) 2002-05-02
US7718705B1 (en) 2010-05-18
EE200200107A (et) 2003-04-15
KR20020025252A (ko) 2002-04-03
CY2012028I1 (el) 2017-04-05
NZ517038A (en) 2003-04-29
DE60026146D1 (de) 2006-04-27
AU6891100A (en) 2001-04-10
TWI312678B (en) 2009-08-01
BG65677B1 (bg) 2009-06-30
ES2256032T3 (es) 2006-07-16
IL148159A0 (en) 2002-09-12
NO2012015I2 (no) 2013-08-26
NO20021035D0 (no) 2002-03-01
HRP20020189A2 (en) 2004-02-29
JP2001089394A (ja) 2001-04-03
WO2001017521A1 (en) 2001-03-15
DE122009000036I1 (de) 2009-11-05
HK1091418A1 (en) 2007-01-19
DE60026146T2 (de) 2006-08-17
TW200524582A (en) 2005-08-01
US20140221497A1 (en) 2014-08-07
AU762934B2 (en) 2003-07-10
KR100719977B1 (ko) 2007-05-21
CZ2002784A3 (cs) 2002-09-11
JP3194734B2 (ja) 2001-08-06
TWI367751B (en) 2012-07-11
EE05315B1 (et) 2010-08-16
DE122009000036I2 (de) 2010-05-06
SI1225881T1 (sl) 2006-06-30
US20050261377A1 (en) 2005-11-24
PL364924A1 (en) 2004-12-27
ZA200201407B (en) 2003-07-30
CZ299712B6 (cs) 2008-10-29
HK1047545A1 (en) 2003-02-28
EA004101B1 (ru) 2003-12-25
IL148159A (en) 2009-11-18
EP1225881A1 (de) 2002-07-31
ES2393582T3 (es) 2012-12-26
CA2383785A1 (en) 2001-03-15
BE2012C040I2 (de) 2019-10-16
CN1222283C (zh) 2005-10-12
EP1225881B1 (de) 2006-02-22
HUP0202687A2 (hu) 2002-12-28
CN1387432A (zh) 2002-12-25
NO330562B1 (no) 2011-05-16
HK1047545B (zh) 2006-09-22
EP1671628B1 (de) 2012-10-03
EP1671628A1 (de) 2006-06-21
CY2012028I2 (el) 2017-04-05
LU92204I2 (fr) 2013-07-23
FR12C0052I1 (de) 2012-05-10
UA75580C2 (uk) 2006-05-15
CA2383785C (en) 2009-02-17
PL211402B1 (pl) 2012-05-31
EA200200324A1 (ru) 2002-08-29

Similar Documents

Publication Publication Date Title
FR12C0052I2 (fr) Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
MXPA03004288A (es) Tratamiento de disfuncion sexual inducida por farmaco antidepresivo con apomorfina.
ES2174318T3 (es) Contorno de un sistema terapeutico transdermico.
CO5050343A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.
CY1118068T1 (el) Η χρηση δαποξετινης, ενος ταχειας-εναρξης επιλεκτικου αναστολεα εκ νεου αναληψης σepοτονινης για την θepαπευτικη αντιμετωπιση σεξουαλικης δυσλειτουργιας
PT1052989E (pt) Utilizacao do 2-amino-6-trifluorometoxibenzotiazole para a prevencao ou o tratamento das disfuncoes do cerebelo
ECSP993026A (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.
EA200000514A1 (ru) Способ лечения эректильной дисфункции
FR2813193B1 (fr) Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central